ADAMTS13 Diagnostic Method for DIC-TTP Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic criteria for disseminated intravascular coagulation (DIC) are inadequate for early diagnosis, often leading to delayed treatment, and differentiate between DIC and thrombotic thrombocytopenic purpura (TTP), as both conditions present with similar symptoms and decreased platelet counts, complicating appropriate therapy.
Innovation Solution
Analyzing the amount and enzyme activity of von Willebrand factor-cleaving protease (ADAMTS13) in patients with DIC to differentiate between DIC and TTP, using a kit with antibodies specific to ADAMTS13 for accurate diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic criteria (platelet count, FDPs, fibrinogen, PT ratio) are used for DIC diagnosis, then a definitive diagnosis can be made, but early diagnosis is delayed and treatment is postponed
Solution Approach 1:
The patent introduces ADAMTS13 measurement as a preliminary diagnostic action that can be performed early in the disease course, before conventional criteria are met. By measuring ADAMTS13 activity and vWF:Ristocetin factor levels at the onset of suspected DIC, the system enables early identification of TTP-DIC overlap syndrome, allowing timely initiation of treatment while preventing progression to severe organ failure.
2Measurement precision
If conventional diagnostic criteria are used, then DIC can be diagnosed, but differentiation between DIC and TTP is difficult due to overlapping symptoms and decreased platelet counts
Solution Approach 1:
The patent segments the diagnostic approach by introducing ADAMTS13 activity measurement and vWF:Ristocetin factor level measurement as separate, specific tests that can distinguish between DIC and TTP. This segmentation allows clinicians to differentiate between the two conditions by evaluating specific biomarkers (ADAMTS13 activity <10% and vWF:Ristocetin factor >100% for TTP-DIC overlap), thereby simplifying the diagnostic decision-making process despite the complexity of the underlying pathology.
3Reliability
If platelet transfusion is administered to patients with decreased platelet counts, then platelet deficiency is corrected, but in TTP cases this may worsen the condition
Solution Approach 1:
The patent implements a feedback mechanism where ADAMTS13 activity measurement and vWF:Ristocetin factor level measurement are used to guide treatment decisions. Before administering platelet transfusion or other therapies, the system evaluates ADAMTS13 activity levels: if ADAMTS13 activity is markedly decreased (<10%), the system feedbacks that TTP-DIC overlap syndrome is present, contraindicating platelet transfusion. This feedback loop prevents harmful treatments while allowing beneficial interventions in pure DIC cases.
Data Source
AI summary
A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.